JP2012530496A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012530496A5 JP2012530496A5 JP2012516307A JP2012516307A JP2012530496A5 JP 2012530496 A5 JP2012530496 A5 JP 2012530496A5 JP 2012516307 A JP2012516307 A JP 2012516307A JP 2012516307 A JP2012516307 A JP 2012516307A JP 2012530496 A5 JP2012530496 A5 JP 2012530496A5
- Authority
- JP
- Japan
- Prior art keywords
- cdr
- seq
- antibody
- binding fragment
- monoclonal antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000012634 fragment Substances 0.000 claims 18
- 230000035772 mutation Effects 0.000 claims 8
- 238000006467 substitution reaction Methods 0.000 claims 6
- 125000003275 alpha amino acid group Chemical group 0.000 claims 5
- 239000000611 antibody drug conjugate Substances 0.000 claims 5
- 229940049595 antibody-drug conjugate Drugs 0.000 claims 5
- 102220250290 rs1554074673 Human genes 0.000 claims 4
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 3
- 102220568015 Merlin_H97E_mutation Human genes 0.000 claims 3
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 229960000397 bevacizumab Drugs 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- 230000001394 metastastic effect Effects 0.000 claims 3
- 206010061289 metastatic neoplasm Diseases 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 229960003876 ranibizumab Drugs 0.000 claims 3
- 102220344151 rs1287146448 Human genes 0.000 claims 3
- 102220465452 Angiogenin_K64Q_mutation Human genes 0.000 claims 2
- 101000808011 Homo sapiens Vascular endothelial growth factor A Proteins 0.000 claims 2
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 102000058223 human VEGFA Human genes 0.000 claims 2
- 208000026278 immune system disease Diseases 0.000 claims 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 2
- 150000007523 nucleic acids Chemical class 0.000 claims 2
- 102000039446 nucleic acids Human genes 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 239000002773 nucleotide Substances 0.000 claims 2
- 125000003729 nucleotide group Chemical group 0.000 claims 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 2
- 102220592281 7SK snRNA methylphosphate capping enzyme_K64S_mutation Human genes 0.000 claims 1
- 208000023328 Basedow disease Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010055114 Colon cancer metastatic Diseases 0.000 claims 1
- 208000015023 Graves' disease Diseases 0.000 claims 1
- 102100026120 IgG receptor FcRn large subunit p51 Human genes 0.000 claims 1
- 101710177940 IgG receptor FcRn large subunit p51 Proteins 0.000 claims 1
- 208000015634 Rectal Neoplasms Diseases 0.000 claims 1
- 206010064930 age-related macular degeneration Diseases 0.000 claims 1
- 102220359630 c.158A>T Human genes 0.000 claims 1
- 102220417854 c.293A>T Human genes 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 208000002780 macular degeneration Diseases 0.000 claims 1
- 238000005259 measurement Methods 0.000 claims 1
- 206010038038 rectal cancer Diseases 0.000 claims 1
- 201000001275 rectum cancer Diseases 0.000 claims 1
- 230000000306 recurrent effect Effects 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US21800509P | 2009-06-17 | 2009-06-17 | |
| US61/218,005 | 2009-06-17 | ||
| PCT/US2010/039029 WO2010148223A2 (en) | 2009-06-17 | 2010-06-17 | Anti-vegf antibodies and their uses |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012530496A JP2012530496A (ja) | 2012-12-06 |
| JP2012530496A5 true JP2012530496A5 (OSRAM) | 2013-08-01 |
| JP5785941B2 JP5785941B2 (ja) | 2015-09-30 |
Family
ID=42543312
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012516307A Expired - Fee Related JP5785941B2 (ja) | 2009-06-17 | 2010-06-17 | 抗ｖｅｇｆ抗体とその使用 |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US9079953B2 (OSRAM) |
| EP (2) | EP2894167B1 (OSRAM) |
| JP (1) | JP5785941B2 (OSRAM) |
| KR (1) | KR20120034739A (OSRAM) |
| CN (1) | CN102482349B (OSRAM) |
| AU (1) | AU2010262836B2 (OSRAM) |
| BR (1) | BRPI1012321A8 (OSRAM) |
| CA (1) | CA2765755C (OSRAM) |
| CL (1) | CL2011003182A1 (OSRAM) |
| CO (1) | CO6480962A2 (OSRAM) |
| CR (1) | CR20110653A (OSRAM) |
| EC (1) | ECSP12011584A (OSRAM) |
| ES (2) | ES2656446T3 (OSRAM) |
| GT (1) | GT201100326A (OSRAM) |
| HK (1) | HK1211961A1 (OSRAM) |
| IL (2) | IL216835A0 (OSRAM) |
| MX (2) | MX2011013781A (OSRAM) |
| NZ (1) | NZ596837A (OSRAM) |
| PE (1) | PE20120622A1 (OSRAM) |
| PH (1) | PH12011502602A1 (OSRAM) |
| RU (1) | RU2567639C2 (OSRAM) |
| SG (2) | SG10201403327WA (OSRAM) |
| TW (1) | TWI510248B (OSRAM) |
| UA (1) | UA104626C2 (OSRAM) |
| WO (1) | WO2010148223A2 (OSRAM) |
| ZA (1) | ZA201109098B (OSRAM) |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8268314B2 (en) | 2008-10-08 | 2012-09-18 | Hoffmann-La Roche Inc. | Bispecific anti-VEGF/anti-ANG-2 antibodies |
| US8765432B2 (en) | 2009-12-18 | 2014-07-01 | Oligasis, Llc | Targeted drug phosphorylcholine polymer conjugates |
| EP2670778A1 (en) * | 2011-02-02 | 2013-12-11 | Glaxo Group Limited | Novel antigen binding proteins |
| US9527925B2 (en) | 2011-04-01 | 2016-12-27 | Boehringer Ingelheim International Gmbh | Bispecific binding molecules binding to VEGF and ANG2 |
| EP2697387B1 (en) * | 2011-04-12 | 2021-09-15 | Bactoclear Holdings PTE. LTD. | Chimeric antibacterial polypeptides |
| PE20150361A1 (es) | 2012-07-13 | 2015-03-14 | Roche Glycart Ag | Anticuerpos biespecificos anti-vegf/anti-ang-2 y su utilizacion en el tratamiento de enfermedades vasculares oculares |
| WO2014047311A1 (en) * | 2012-09-19 | 2014-03-27 | Genentech, Inc. | Methods and compositions for preventing norleucine misincorporation into proteins |
| US9777067B2 (en) | 2012-09-27 | 2017-10-03 | Massachusetts Institute Of Technology | HER2- and VEGF-A-binding proteins with enhanced stability |
| KR101279895B1 (ko) * | 2012-10-24 | 2013-06-28 | 주식회사 진흥기공 | 유체 이송용 덕트에 결합 사용되는 댐퍼의 이중 브레이드 밀폐 장치 |
| US20140154255A1 (en) * | 2012-11-30 | 2014-06-05 | Abbvie Biotherapeutics Inc. | Anti-vegf antibodies and their uses |
| EA031025B1 (ru) | 2012-12-21 | 2018-11-30 | Сиэтл Дженетикс, Инк. | Антитела против ntb-a и связанные с ними композиции и способы |
| US9707154B2 (en) | 2013-04-24 | 2017-07-18 | Corning Incorporated | Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients |
| MX368142B (es) * | 2013-04-30 | 2019-09-20 | Intas Pharmaceuticals Ltd | Metodo de clonacion, expresion y purificacion novedoso para la preparacion de ranibizumab. |
| EP3019243A4 (en) * | 2013-07-12 | 2017-03-15 | Ophthotech Corporation | Methods for treating or preventing ophthalmological conditions |
| PL3041513T3 (pl) | 2013-09-08 | 2021-01-25 | Kodiak Sciences Inc. | Obojnaczojonowe polimerowe koniugaty czynnika viii |
| JP6983511B2 (ja) | 2014-04-25 | 2021-12-17 | ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア | 脳中の転移乳癌および他の癌を処置するための方法および組成物 |
| US9840553B2 (en) | 2014-06-28 | 2017-12-12 | Kodiak Sciences Inc. | Dual PDGF/VEGF antagonists |
| TWI719939B (zh) * | 2014-07-14 | 2021-03-01 | 日商中外製藥股份有限公司 | 鑑定蛋白質抗原決定位之方法 |
| WO2016061562A2 (en) | 2014-10-17 | 2016-04-21 | Kodiak Sciences Inc. | Butyrylcholinesterase zwitterionic polymer conjugates |
| CN105820245B (zh) * | 2015-01-06 | 2018-03-13 | 珠海亿胜生物制药有限公司 | 抗vegf抗体 |
| AU2016381964B2 (en) * | 2015-12-30 | 2024-02-15 | Kodiak Sciences Inc. | Antibodies and conjugates thereof |
| KR20240005973A (ko) * | 2016-04-15 | 2024-01-12 | 리젠엑스바이오 인크. | 완전히-인간형의 번역후 변형된 항-VEGF Fab를 이용한 눈 질환의 치료 |
| IL262207B1 (en) | 2016-04-15 | 2025-09-01 | Univ Pennsylvania | Compositions for treatment of wet age-related macular degeneration |
| CN106039309B (zh) * | 2016-06-30 | 2024-04-19 | 中国人民解放军总医院第一附属医院 | 用于治疗恶性肿瘤造成的胸腔积液的药物组合物及其应用 |
| RU2656160C2 (ru) | 2016-08-17 | 2018-05-31 | Закрытое Акционерное Общество "Биокад" | Антитело или его антигенсвязывающий фрагмент, способный связываться с рецептором интерлейкина-6 человека |
| WO2019067540A1 (en) * | 2017-09-27 | 2019-04-04 | Regenxbio Inc. | TREATMENT OF OCULAR DISEASES WITH A TOTALLY HUMAN POST-TRANSLATIONAL MODIFICATION ANTI-VEGF FAB |
| MY207644A (en) * | 2017-12-19 | 2025-03-07 | Akouos Inc | Aav-mediated delivery of therapeutic antibodies to the inner ear |
| US20210093734A1 (en) * | 2018-02-20 | 2021-04-01 | The Trustees Of The University Of Pennsylvania | Compositions for treatment of wet age-realted macular degeneration |
| CN112203679A (zh) | 2018-03-02 | 2021-01-08 | 科达制药股份有限公司 | Il-6抗体及其融合构建体和缀合物 |
| CN109053895B (zh) | 2018-08-30 | 2020-06-09 | 中山康方生物医药有限公司 | 抗pd-1-抗vegfa的双功能抗体、其药物组合物及其用途 |
| US20200115443A1 (en) * | 2018-10-12 | 2020-04-16 | Trican Biotechnology Co., Ltd | Bi-functional fusion proteins and uses thereof |
| CN111423512B (zh) * | 2019-01-10 | 2024-01-05 | 北京比洋生物技术有限公司 | 阻断血管内皮细胞生长且活化t细胞的多靶向融合蛋白和包含其的药物组合物 |
| CA3157509A1 (en) | 2019-10-10 | 2021-04-15 | Kodiak Sciences Inc. | Methods of treating an eye disorder |
| CN111363038A (zh) * | 2020-03-26 | 2020-07-03 | 北京纽安博生物技术有限公司 | 抗VEGF单域抗体及其人源化、单域抗体和IgG1-Fc构建的融合蛋白和应用 |
| CN111808191A (zh) * | 2020-05-11 | 2020-10-23 | 廊坊天光生物技术有限公司 | 一种用于检测血清中vegf含量的抗体对及其用途 |
| EP4206226A4 (en) * | 2020-08-31 | 2024-10-16 | Medytox Inc. | Anti-vegf hexameric antibody and composition comprising same |
| WO2022119839A1 (en) | 2020-12-01 | 2022-06-09 | Akouos, Inc. | Anti-vegf antibody constructs and related methods for treating vestibular schwannoma associated symptoms |
| CN116897052A (zh) * | 2021-03-04 | 2023-10-17 | 百奥泰生物制药股份有限公司 | 抗vegf抗体制剂 |
| AU2023215253A1 (en) | 2022-02-02 | 2024-09-19 | Akouos, Inc. | Anti-vegf antibody constructs and related methods for treating vestibular schwannoma associated symptoms |
| CN120248142B (zh) * | 2025-06-06 | 2025-09-12 | 上海兴瑞一达生物科技有限公司 | 一种共表达cd47和il-15的双靶点嵌合抗原受体、car-t细胞及其应用 |
Family Cites Families (91)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4444887A (en) | 1979-12-10 | 1984-04-24 | Sloan-Kettering Institute | Process for making human antibody producing B-lymphocytes |
| US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4634665A (en) | 1980-02-25 | 1987-01-06 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US5179017A (en) | 1980-02-25 | 1993-01-12 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4716111A (en) | 1982-08-11 | 1987-12-29 | Trustees Of Boston University | Process for producing human antibodies |
| US4510245A (en) | 1982-11-18 | 1985-04-09 | Chiron Corporation | Adenovirus promoter system |
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
| GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
| US5168062A (en) | 1985-01-30 | 1992-12-01 | University Of Iowa Research Foundation | Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence |
| US4737456A (en) | 1985-05-09 | 1988-04-12 | Syntex (U.S.A.) Inc. | Reducing interference in ligand-receptor binding assays |
| US4968615A (en) | 1985-12-18 | 1990-11-06 | Ciba-Geigy Corporation | Deoxyribonucleic acid segment from a virus |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| GB8720833D0 (en) | 1987-09-04 | 1987-10-14 | Celltech Ltd | Recombinant dna product |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| GB8907617D0 (en) | 1989-04-05 | 1989-05-17 | Celltech Ltd | Drug delivery system |
| US5413923A (en) | 1989-07-25 | 1995-05-09 | Cell Genesys, Inc. | Homologous recombination for universal donor cells and chimeric mammalian hosts |
| US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
| GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
| EP1690935A3 (en) | 1990-01-12 | 2008-07-30 | Abgenix, Inc. | Generation of xenogeneic antibodies |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| JP2938569B2 (ja) | 1990-08-29 | 1999-08-23 | ジェンファーム インターナショナル，インコーポレイティド | 異種免疫グロブリンを作る方法及びトランスジェニックマウス |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
| EP0519596B1 (en) | 1991-05-17 | 2005-02-23 | Merck & Co. Inc. | A method for reducing the immunogenicity of antibody variable domains |
| US5264586A (en) | 1991-07-17 | 1993-11-23 | The Scripps Research Institute | Analogs of calicheamicin gamma1I, method of making and using the same |
| MX9204374A (es) | 1991-07-25 | 1993-03-01 | Idec Pharma Corp | Anticuerpo recombinante y metodo para su produccion. |
| US5565332A (en) | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
| WO1993011236A1 (en) | 1991-12-02 | 1993-06-10 | Medical Research Council | Production of anti-self antibodies from antibody segment repertoires and displayed on phage |
| US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
| US5635483A (en) | 1992-12-03 | 1997-06-03 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Tumor inhibiting tetrapeptide bearing modified phenethyl amides |
| US5780588A (en) | 1993-01-26 | 1998-07-14 | Arizona Board Of Regents | Elucidation and synthesis of selected pentapeptides |
| US5773001A (en) | 1994-06-03 | 1998-06-30 | American Cyanamid Company | Conjugates of methyltrithio antitumor agents and intermediates for their synthesis |
| DE69637481T2 (de) | 1995-04-27 | 2009-04-09 | Amgen Fremont Inc. | Aus immunisierten Xenomäusen stammende menschliche Antikörper gegen IL-8 |
| EP0823941A4 (en) | 1995-04-28 | 2001-09-19 | Abgenix Inc | HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES |
| US5714586A (en) | 1995-06-07 | 1998-02-03 | American Cyanamid Company | Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates |
| US5712374A (en) | 1995-06-07 | 1998-01-27 | American Cyanamid Company | Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates |
| US5834597A (en) | 1996-05-20 | 1998-11-10 | Protein Design Labs, Inc. | Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same |
| US5916771A (en) | 1996-10-11 | 1999-06-29 | Abgenix, Inc. | Production of a multimeric protein by cell fusion method |
| ES2301183T3 (es) | 1996-12-03 | 2008-06-16 | Amgen Fremont Inc. | Anticuerpo completamente humano que se une al receptor del egfr. |
| GB9625640D0 (en) | 1996-12-10 | 1997-01-29 | Celltech Therapeutics Ltd | Biological products |
| US20020032315A1 (en) * | 1997-08-06 | 2002-03-14 | Manuel Baca | Anti-vegf antibodies |
| ES2361267T3 (es) * | 1997-04-07 | 2011-06-15 | Genentech Inc. | Procedimiento para la produccion de anticuerpos humanizados mediante mutagénesis aleatoria. |
| US20070059302A1 (en) | 1997-04-07 | 2007-03-15 | Genentech, Inc. | Anti-vegf antibodies |
| US6884879B1 (en) | 1997-04-07 | 2005-04-26 | Genentech, Inc. | Anti-VEGF antibodies |
| CN100387621C (zh) | 1997-04-14 | 2008-05-14 | 麦可麦脱股份公司 | 抗人抗原受体的新的生产方法及其用途 |
| US6235883B1 (en) | 1997-05-05 | 2001-05-22 | Abgenix, Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
| JP2002530081A (ja) | 1998-11-18 | 2002-09-17 | ジェネンテック・インコーポレーテッド | 親抗体より高度な結合親和性を持つ抗体変異体 |
| SI1135498T1 (sl) | 1998-11-18 | 2008-06-30 | Genentech Inc | Variante protitelesa z višjo vezavno afiniteto vprimerjavi z izvirnimi protitelesi |
| ATE300957T1 (de) | 1998-12-22 | 2005-08-15 | Genentech Inc | Antagonisten von vaskular-endothelialen zellwachstumsfaktoren und ihre anwendung |
| US6979559B2 (en) | 2000-10-12 | 2005-12-27 | Marical, Inc. | Polyvalent cation-sensing receptor in atlantic salmon |
| DK1356052T3 (da) | 2000-12-14 | 2008-12-08 | Genentech Inc | Produktion af hele antistoffer i prokaryotiske celler |
| US6979556B2 (en) | 2000-12-14 | 2005-12-27 | Genentech, Inc. | Separate-cistron contructs for secretion of aglycosylated antibodies from prokaryotes |
| BR0116680A (pt) | 2000-12-14 | 2005-04-05 | Genentech Inc | Linhagem de e. coli e método de produção de um polipeptìdeo |
| CA2369893A1 (en) | 2001-02-12 | 2002-08-12 | Warner-Lambert Company | Vegf responsive cell-based assay for determining vegf bioactivity |
| US20040010376A1 (en) | 2001-04-17 | 2004-01-15 | Peizhi Luo | Generation and selection of protein library in silico |
| US7117096B2 (en) | 2001-04-17 | 2006-10-03 | Abmaxis, Inc. | Structure-based selection and affinity maturation of antibody library |
| US7667004B2 (en) * | 2001-04-17 | 2010-02-23 | Abmaxis, Inc. | Humanized antibodies against vascular endothelial growth factor |
| US20030022240A1 (en) | 2001-04-17 | 2003-01-30 | Peizhi Luo | Generation and affinity maturation of antibody library in silico |
| US6884869B2 (en) | 2001-04-30 | 2005-04-26 | Seattle Genetics, Inc. | Pentapeptide compounds and uses related thereto |
| BR0307548A (pt) | 2002-02-11 | 2006-01-17 | Genentech Inc | Método de produção de uma variante de anticorpo, variante de anticorpo, composição, ácido nucléico isolado, vetor, célula hospedeira, processo para a produção de uma variante de anticorpo e método de determinação do coeficiente de associação de antìgeno de um anticorpo |
| CN1672160B (zh) * | 2002-05-20 | 2010-06-09 | 埃博马可西斯公司 | 基于前导抗体的结构构建抗体文库的方法 |
| US7217797B2 (en) | 2002-10-15 | 2007-05-15 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
| AU2003287345A1 (en) | 2002-10-31 | 2004-06-07 | Genentech, Inc. | Methods and compositions for increasing antibody production |
| US7575893B2 (en) | 2003-01-23 | 2009-08-18 | Genentech, Inc. | Methods for producing humanized antibodies and improving yield of antibodies or antigen binding fragments in cell culture |
| RS20150135A1 (sr) | 2003-05-30 | 2015-08-31 | Genentech Inc. | Tretman sa anti-vegf antitelima |
| EP3095793B1 (en) | 2003-07-28 | 2020-03-25 | Genentech, Inc. | Reducing protein a leaching during protein a affinity chromatography |
| CN104998273A (zh) | 2003-11-06 | 2015-10-28 | 西雅图基因公司 | 能够与配体偶联的单甲基缬氨酸化合物 |
| WO2005123780A2 (en) | 2004-04-09 | 2005-12-29 | Protein Design Labs, Inc. | Alteration of fcrn binding affinities or serum half-lives of antibodies by mutagenesis |
| US20060182783A1 (en) | 2004-04-30 | 2006-08-17 | Allergan, Inc. | Sustained release intraocular drug delivery systems |
| US20070059336A1 (en) | 2004-04-30 | 2007-03-15 | Allergan, Inc. | Anti-angiogenic sustained release intraocular implants and related methods |
| GB0412181D0 (en) | 2004-06-01 | 2004-06-30 | Celltech R&D Ltd | Biological products |
| KR20070057839A (ko) | 2004-08-19 | 2007-06-07 | 제넨테크, 인크. | 변경된 이펙터 기능을 갖는 폴리펩티드 변이체 |
| RU2007117716A (ru) | 2004-10-12 | 2008-11-20 | Ампротеин Корпорейшн (Us) | Химерный белок |
| EP1799246A4 (en) | 2004-10-12 | 2009-08-12 | Amprotein Corp | CHIMERIC PROTEIN |
| JO3000B1 (ar) | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
| US7632497B2 (en) | 2004-11-10 | 2009-12-15 | Macrogenics, Inc. | Engineering Fc Antibody regions to confer effector function |
| US20080207467A1 (en) | 2005-03-03 | 2008-08-28 | Xencor, Inc. | Methods for the design of libraries of protein variants |
| WO2007054816A2 (en) | 2005-11-14 | 2007-05-18 | Bioren, Inc. | Antibody ultrahumanization by predicted mature cdr blasting and cohort library generation and screening |
| WO2007059336A1 (en) | 2005-11-18 | 2007-05-24 | Nextrom Oy | Method and apparatus for manufacturing water-free optical fiber preforms |
| US7820165B2 (en) | 2005-11-21 | 2010-10-26 | Merck Serono, S.A. | Compositions and methods of producing hybrid antigen binding molecules and uses thereof |
| KR101535678B1 (ko) | 2006-01-23 | 2015-07-09 | 조셉 피. 에리코 | 표적 약물 개발의 방법 및 조성물 |
| ES2603399T3 (es) | 2006-07-10 | 2017-02-27 | Esbatech, An Alcon Biomedical Research Unit Llc | Anticuerpos scFv que atraviesan capas epiteliales y/o endoteliales |
| US11078262B2 (en) | 2007-04-30 | 2021-08-03 | Allergan, Inc. | High viscosity macromolecular compositions for treating ocular conditions |
| HUE046992T2 (hu) | 2007-07-09 | 2020-04-28 | Genentech Inc | Diszulfidkötés redukciójának megelõzése polipeptidek rekombináns elõállítása során |
| WO2009129538A2 (en) | 2008-04-18 | 2009-10-22 | Xencor, Inc. | Human equivalent monoclonal antibodies engineered from nonhuman variable regions |
-
2010
- 2010-06-17 US US12/817,800 patent/US9079953B2/en not_active Expired - Fee Related
- 2010-06-17 CA CA2765755A patent/CA2765755C/en not_active Expired - Fee Related
- 2010-06-17 EP EP14197237.2A patent/EP2894167B1/en not_active Not-in-force
- 2010-06-17 NZ NZ596837A patent/NZ596837A/en not_active IP Right Cessation
- 2010-06-17 KR KR1020127001157A patent/KR20120034739A/ko not_active Withdrawn
- 2010-06-17 PE PE2011002096A patent/PE20120622A1/es not_active Application Discontinuation
- 2010-06-17 MX MX2011013781A patent/MX2011013781A/es active IP Right Grant
- 2010-06-17 EP EP10725590.3A patent/EP2443150B1/en active Active
- 2010-06-17 TW TW099119749A patent/TWI510248B/zh not_active IP Right Cessation
- 2010-06-17 MX MX2014001638A patent/MX346002B/es unknown
- 2010-06-17 SG SG10201403327WA patent/SG10201403327WA/en unknown
- 2010-06-17 RU RU2011150916/10A patent/RU2567639C2/ru not_active IP Right Cessation
- 2010-06-17 ES ES14197237.2T patent/ES2656446T3/es active Active
- 2010-06-17 SG SG2011093473A patent/SG177265A1/en unknown
- 2010-06-17 BR BRPI1012321A patent/BRPI1012321A8/pt not_active IP Right Cessation
- 2010-06-17 UA UAA201114515A patent/UA104626C2/ru unknown
- 2010-06-17 CN CN201080027121.5A patent/CN102482349B/zh not_active Expired - Fee Related
- 2010-06-17 PH PH1/2011/502602A patent/PH12011502602A1/en unknown
- 2010-06-17 ES ES10725590.3T patent/ES2534355T3/es active Active
- 2010-06-17 JP JP2012516307A patent/JP5785941B2/ja not_active Expired - Fee Related
- 2010-06-17 WO PCT/US2010/039029 patent/WO2010148223A2/en not_active Ceased
- 2010-06-17 AU AU2010262836A patent/AU2010262836B2/en not_active Ceased
-
2011
- 2011-12-06 CR CR20110653A patent/CR20110653A/es unknown
- 2011-12-07 IL IL216835A patent/IL216835A0/en not_active IP Right Cessation
- 2011-12-09 ZA ZA2011/09098A patent/ZA201109098B/en unknown
- 2011-12-15 CL CL2011003182A patent/CL2011003182A1/es unknown
- 2011-12-16 GT GT201100326A patent/GT201100326A/es unknown
- 2011-12-28 CO CO11179622A patent/CO6480962A2/es not_active Application Discontinuation
-
2012
- 2012-01-09 EC ECSP12011584 patent/ECSP12011584A/es unknown
-
2015
- 2015-06-23 IL IL239604A patent/IL239604A/en not_active IP Right Cessation
- 2015-12-30 HK HK15112838.4A patent/HK1211961A1/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012530496A5 (OSRAM) | ||
| US10465014B2 (en) | PDL-1 antibody, pharmaceutical composition thereof, and uses thereof | |
| CN109608544B (zh) | Pd-l1抗体、其抗原结合片段及其医药用途 | |
| JP2016512551A5 (OSRAM) | ||
| JP2011046732A5 (OSRAM) | ||
| JP2012525829A5 (OSRAM) | ||
| JP2016536020A5 (OSRAM) | ||
| JP2017052784A5 (OSRAM) | ||
| JP2013529059A5 (OSRAM) | ||
| JP2016505546A5 (OSRAM) | ||
| RU2011150916A (ru) | Антитела против vegf и их применения | |
| JP2018510617A5 (OSRAM) | ||
| JP2018503380A5 (OSRAM) | ||
| JP2020514277A5 (OSRAM) | ||
| JP2014503209A5 (OSRAM) | ||
| JP2014526898A5 (OSRAM) | ||
| RU2019121086A (ru) | Иммунотерапия с применением антител, связывающих лиганд 1 белка программируемой смерти клеток (PD-L1) | |
| JP2010526028A5 (OSRAM) | ||
| JP7679399B2 (ja) | 抗ｆｌｔ３抗体及び組成物 | |
| JP2020502233A5 (OSRAM) | ||
| US20250051467A1 (en) | Fap/cd40 binding molecule and medicinal use thereof | |
| EA039946B1 (ru) | Антитела-антагонисты к интерферону альфа и интерферону омега | |
| JP2010509931A5 (OSRAM) | ||
| CN111886023A (zh) | 针对tim-3的抗体及其用途 | |
| JP2022527935A (ja) | Ｃｄ３結合分子 |